GlassScriptPhysician profile
Erin Lancaster
NPI 1104399393
$1,579.85
in general payments reported to CMS, 2019-2025
21 companies · $736 in 2025
The $736 reported for 2025 was more than what 82% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $15.73 · 2023: $198 · 2024: $630 · 2025: $736.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,379 · Education: $185.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,379.14 |
| Education | $184.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $455.74 | 2024-2025 | Erleada |
| Astellas Pharma US INC | $246.07 | 2024-2025 | Xtandi |
| Bayer Healthcare Pharmaceuticals INC. | $230.73 | 2024-2025 | |
| Urogen Pharma, INC. | $116.45 | 2024-2025 | |
| Kowa Pharmaceuticals America, INC. | $89.63 | 2023 | Seglentis |
| Tolmar, INC. | $45.01 | 2025 | Eligard, Jatenzo |
| Sumitomo Pharma America, INC. | $43.37 | 2024-2025 | Gemtesa |
| Bioventus LLC | $41.88 | 2023 | Durolane |
| Abbvie INC. | $40.97 | 2024 | |
| 180 Medical, INC. | $34.54 | 2024-2025 | Cure Catheter |
| Dynasplint Systems INC. | $29.91 | 2023 | Dynasplint |
| Progenics Pharmaceuticals, INC. | $25.72 | 2024 | |
| Vertex Pharmaceuticals Incorporated | $25.54 | 2024 | |
| Photocure INC | $21.91 | 2025 | Cysview |
| Vericel Corporation | $20.64 | 2023 | Maci |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myriad Genetic Laboratories, INC. | $20.34 | 2024 | Prolaris |
| Immunitybio, INC. | $20.23 | 2025 | |
| Ferring Pharmaceuticals INC. | $20.06 | 2025 | Adstiladrin |
| Novo Nordisk INC | $19.67 | 2024 | Rybelsus, Ozempic |
| Smith+Nephew, INC. | $15.73 | 2021 | |
| Organogenesis INC. | $15.71 | 2023 | Puraply |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erin Lancaster listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.